OTCPK:BIXT

Stock Analysis Report

Executive Summary

Bioxytran, Inc., an early stage pharmaceutical company, focuses on the development, manufacture, and commercialization of various therapeutic drugs to address hypoxia in humans.

Risk Analysis

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

Shareholders have been diluted in the past year

+ 1 more risk


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has Bioxytran's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BIXT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

113.8%

BIXT

-0.5%

US Biotechs

1.5%

US Market


1 Year Return

5.9%

BIXT

11.0%

US Biotechs

20.1%

US Market

Return vs Industry: BIXT underperformed the US Biotechs industry which returned 11% over the past year.

Return vs Market: BIXT underperformed the US Market which returned 20.1% over the past year.


Shareholder returns

BIXTIndustryMarket
7 Day113.8%-0.5%1.5%
30 Day80.0%0.6%1.4%
90 Day-22.4%9.3%8.7%
1 Year5.9%5.9%12.0%11.0%22.7%20.1%
3 Yearn/a16.9%13.6%50.1%40.5%
5 Yearn/a-1.5%-6.2%73.1%54.1%

Price Volatility Vs. Market

How volatile is Bioxytran's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Bioxytran undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Bioxytran is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Bioxytran has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of BIXT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Bioxytran regulatory filings here.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Bioxytran forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

20.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bioxytran has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Bioxytran performed over the past 5 years?

-367.5%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: BIXT is currently unprofitable.

Growing Profit Margin: BIXT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if BIXT's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare BIXT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BIXT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (66.2%).


Return on Equity

High ROE: BIXT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Bioxytran's financial position?


Financial Position Analysis

Short Term Liabilities: BIXT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: BIXT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: BIXT has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: BIXT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: BIXT has a low level of unsold assets or inventory.

Debt Coverage by Assets: BIXT has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BIXT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BIXT has less than a year of cash runway if free cash flow continues to reduce at historical rates of -96.5% each year


Next Steps

Dividend

What is Bioxytran's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate BIXT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BIXT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BIXT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BIXT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BIXT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

US$18k

CEO Compensation


CEO

David Platt (66yo)

1.4yrs

Tenure

US$18,000

Compensation

Dr. David Platt, Ph.D. serves as President, Chief Executive Officer and Chairman of Board of Directors at Bioxytran, Inc. Dr. Platt founded Boston Therapeutics, Inc. (also known as AVANYX Therapeutics, Inc ...


CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD18.00K) is below average for companies of similar size in the US market ($USD521.92K).

Compensation vs Earnings: Insufficient data to compare David's compensation with company performance.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.3%.


Top Shareholders

Company Information

Bioxytran, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bioxytran, Inc.
  • Ticker: BIXT
  • Exchange: OTCPK
  • Founded: 2017
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$38.914m
  • Shares outstanding: 86.48m
  • Website: https://www.bioxytraninc.com

Location

  • Bioxytran, Inc.
  • 233 Needham Street
  • Suite 300
  • Newton
  • Massachusetts
  • 2464
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIXTOTCPK (Pink Sheets LLC)YesCommon StockUSUSDSep 2018

Biography

Bioxytran, Inc., an early stage pharmaceutical company, focuses on the development, manufacture, and commercialization of various therapeutic drugs to address hypoxia in humans. The company’s lead pharmaceutical drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for the treatment of patients with ischemia of the brain resulting from a stroke or the blockage of the blood vessels to the brain. Its products also include BXT-252, an injectable anti-necrosis drug to treat a wound that does not heal because limited amount of oxygen reaching the wound. The company was founded in 2017 and is headquartered in Newton, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/17 01:03
End of Day Share Price2020/02/14 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.